Markets Insider: Yaqrit Phase 2a data, clinical consensus boost YAQ007 and YAQ006 in Hepatic Encephalopathy
Yaqrit Phase 2a data, clinical consensus boost YAQ007 and YAQ006 in Hepatic Encephalopathy
The American Journal of Managed Care: Clinical Features and Risk Factors of Hepatic Encephalopathy and Their Impact on Patient Care
Clinical Features and Risk Factors of Hepatic Encephalopathy and Their Impact on Patient Care
MarketWatch: Yaqrit Phase 2a data, clinical consensus boost YAQ007 and YAQ006 in Hepatic Encephalopathy
Bausch Health’s gastroenterology business arm, Salix, is using its new spot for Xifaxan to educate patients with cirrhosis of the liver about the risk of overt hepatic encephalopathy (OHE). Up to 80% ...
Strong global consensus on measurement and role of ammonia in Hepatic Encephalopathy (HE)Phase 2a results of YAQ007 (oral OPA) show ammonia ...
In a clinical guideline issued by the American College of Gastroenterology and published in the March issue of the American Journal of Gastroenterology, recommendations are presented for the diagnosis ...
Roughly half as many patients with cirrhosis in remission from overt hepatic encephalopathy (OHE) experienced a breakthrough episode with rifaximin monotherapy compared with lactulose monotherapy, a ...
Healio: Rifaximin reduces risk for overt hepatic encephalopathy recurrence by 60% vs. lactulose
Rifaximin reduces risk for overt hepatic encephalopathy recurrence by 60% vs. lactulose
Dr. Arun Jesudian explains that hepatic encephalopathy (HE) is a reversible neuropsychiatric syndrome in cirrhosis patients, often undiagnosed due to asymptomatic progression. Stay ahead of policy, ...
Healio: Q&A: Phase 2 trial will assess AXA1665’s ability to reduce overt hepatic encephalopathy